Stemline Therapeutics, Inc. (STML) Stake Raised by Ameriprise Financial Inc.

Ameriprise Financial Inc. increased its stake in Stemline Therapeutics, Inc. (NASDAQ:STML) by 8.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,900 shares of the biopharmaceutical company’s stock after buying an additional 3,500 shares during the period. Ameriprise Financial Inc. owned 0.24% of Stemline Therapeutics worth $375,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in STML. Wells Fargo & Company MN raised its position in shares of Stemline Therapeutics by 3.8% in the first quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 500 shares in the last quarter. Nationwide Fund Advisors raised its position in shares of Stemline Therapeutics by 7.8% in the first quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 858 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 4,800 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Stemline Therapeutics by 30.8% in the fourth quarter. Teachers Advisors LLC now owns 35,195 shares of the biopharmaceutical company’s stock valued at $377,000 after buying an additional 8,282 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. raised its position in shares of Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 11,300 shares in the last quarter. 54.18% of the stock is owned by institutional investors.

Stemline Therapeutics, Inc. (NASDAQ STML) opened at 10.20 on Friday. Stemline Therapeutics, Inc. has a 12-month low of $5.50 and a 12-month high of $14.60. The firm’s market capitalization is $238.44 million. The stock has a 50 day moving average of $8.75 and a 200 day moving average of $8.81.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.30 million. Stemline Therapeutics had a negative net margin of 3,864.20% and a negative return on equity of 60.51%. Equities research analysts anticipate that Stemline Therapeutics, Inc. will post ($2.27) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Stemline Therapeutics, Inc. (STML) Stake Raised by Ameriprise Financial Inc.” was reported by BBNS and is the property of of BBNS. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://baseballnewssource.com/markets/stemline-therapeutics-inc-stml-stake-raised-by-ameriprise-financial-inc/1259038.html.

Several brokerages have weighed in on STML. ValuEngine lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 31st. HC Wainwright reissued a “buy” rating on shares of Stemline Therapeutics in a report on Monday, May 15th. BidaskClub raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 20th. Finally, Wedbush raised their price objective on shares of Stemline Therapeutics from $33.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, May 11th. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Stemline Therapeutics has a consensus rating of “Buy” and an average price target of $29.17.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics, Inc. (NASDAQ:STML).

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Colin Moran Fouls Ball Off Eye, Taken to Hospital
Colin Moran Fouls Ball Off Eye, Taken to Hospital
Chris Sale Reaches 200 Strikeouts in Record Time
Chris Sale Reaches 200 Strikeouts in Record Time
Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided


Leave a Reply

 
© 2006-2017 BBNS.